Company intelligence / Profile preview

WaveForm Diabetes

Salem, New Hampshire, United States

Ownership: Private
Employees: ~149
Development stage: Other

Overview

Prior to acquisition, eight human clinical studies had been completed by Bayer Healthcare showing significant potential for the CGM technology. Additional trials by WaveForm suggest comparable accuracy and performance to marketed CGMs; targeting CE mark (Europe) in 2018 and U.S. clinical trials for PMA submission as early as 2019[2].

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Bayer Healthcare (past CGM asset acquisition and China partnership)

Beyond the preview

Go deeper on WaveForm Diabetes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WaveForm Diabetes.

Explore the full profile